ACE-083_Dosage, benefits & legal status
Also known as ACE083
A muscle drug injected into one muscle at a time. It grew muscle and changed nothing functional.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is ACE-083?
Plain language first. The technical label stays, but it never stands alone.Overview
An injection into one muscle that makes that muscle grow. In two phase 2 trials the muscle got bigger and function did not improve.
ACE-083 is a locally acting follistatin-based fusion protein that binds TGF-beta superfamily ligands including myostatin and activins, given by intramuscular injection into a target muscle so the effect stays local.
What it's used for
Sold for muscle growth. Its own trials are the reason to be careful about what muscle volume means.
How does ACE-083 work?
What it does in the body, and where.ACE-083 was designed to solve a specific problem with myostatin blockers: they work everywhere, and you may only want one muscle to grow.
- 01It soaks up growth-limiting signalsFollistatin naturally binds myostatin and activins, which hold muscle growth back.
- 02It stays where it is injectedThe molecule was engineered to remain in the muscle it is put into, which is why trials targeted the tibialis anterior and biceps.
- 03The muscle grew and nothing else changedVolume rose by more than 12 to 15% in treated muscles. Strength, function and patient-reported scores did not improve, and the programme was stopped in 2019 for FSHD and March 2020 for CMT.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Local muscle growth in a targeted muscleInvestigational
- Strength or functionInvestigational

At a glance
Four things to know about ACE-083
Evidence
Investigational
Category
Muscle building
Common vial
Varies
Half-life
Nothing published in humans
How much, and do you cycle it?
The range, and whether you take breaks.200 to 240 mg into one named muscle, in the trial, every 3 weeks in the trial. No established patternNo range
No published human study establishes a schedule.
How long does it stay in the body?
The half-life, and where the figure comes from.Nothing published in humansNo figure
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
10000 / 100 unitsACE-083 starts at $55.99 across 1 vendor.
1 listing, last read Sep 12, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized ACE-083 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- No approved use exists
- Pregnancy
Stop and get help
- Spreading swelling, redness or heat at an injection site
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Injection-site pain and swelling
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is ACE-083 approved?
And where the numbers on this page come from.No. ACE-083 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteInto the muscle (intramuscular), in the trials
- Checked24 September 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Never approved. Held FDA fast track and orphan drug designations for FSHD and CMT before development stopped.
You can compare this against the whole library, or read how to check a seller.
What else is like ACE-083?
Others in Muscle building, side by side.If you're weighing ACE-083, it's worth reading Bimagrumab, Ipamorelin + CJC-1295 (no DAC) blend, and IGF-1 LR3 in the same class.
A muscle drug injected into one muscle at a time. It grew muscle and changed nothing functional.
- Dose
- 200 to 240 mg into one named muscle, in the trial
- How often
- Every 3 weeks in the trial
An experimental shot that strips fat while adding muscle.
- Dose
- 10 up to 30 mg/kg per month (trial doses)
- How often
- Monthly
The popular growth-hormone combo in one shot, for muscle, recovery, and sleep.
- Dose
- ~0.1 mg CJC-1295 per dose (the ipamorelin follows your ratio)
- How often
- Daily, often at night
A powerful muscle-builder that also drops blood sugar hard.
- Dose
- 0.02 up to 0.05 mg per day (start low, increase slowly)
- How often
- Daily, cycled
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Statland JM, et al. Randomized phase 2 study of ACE-083 in facioscapulohumeral muscular dystrophy. Muscle Nerve(2022)Treated muscle volume rose, and no functional or patient-reported measure improved.
- Acceleron discontinues ACE-083 for Charcot-Marie-Tooth after phase 2(2020)Muscle volume met the primary endpoint; every functional and quality-of-life secondary endpoint missed, ending the programme.
Last reviewed 24 September 2026
